Aoxing Pharmaceutical Co (Aoxing Pharmaceutical Co) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2017)

View and export this data going back to 2001. Start your Free Trial

What is Aoxing Pharmaceutical Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Aoxing Pharmaceutical Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2017 was 0.00.

Aoxing Pharmaceutical Co's long-term debt to total assets ratio increased from Mar. 2016 (0.00) to Mar. 2017 (0.00). It may suggest that Aoxing Pharmaceutical Co is progressively becoming more dependent on debt to grow their business.

Aoxing Pharmaceutical Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Aoxing Pharmaceutical Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aoxing Pharmaceutical Co LT-Debt-to-Total-Asset Chart

Aoxing Pharmaceutical Co Annual Data

Trend

Jun07

Jun08

Jun09

Jun10

Jun11

Jun12

Jun13

Jun14

Jun15

Jun16

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.33

0.20

0.03

Aoxing Pharmaceutical Co Quarterly Data
	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Aoxing Pharmaceutical Co LT-Debt-to-Total-Asset Calculation

Aoxing Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2016 is calculated as

LT Debt to Total Assets (A: Jun. 2016 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2016 )	/	Total Assets (A: Jun. 2016 )
	=	0	/	56.232
	=	0.00

Aoxing Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2017 is calculated as

LT Debt to Total Assets (Q: Mar. 2017 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2017 )	/	Total Assets (Q: Mar. 2017 )
	=	0.1	/	62.466
	=	0.00

Aoxing Pharmaceutical Co (OTCPK:AOXG) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Aoxing Pharmaceutical Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Aoxing Pharmaceutical Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Aoxing Pharmaceutical Co (Aoxing Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aoxing Pharmaceutical Co Inc (OTCPK:AOXG) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

624 Tyvola Road, Suite 103, No. 186, Charlotte, NC, USA, 28217

Website

http://www.aoxingpharma.com

Aoxing Pharmaceutical Co Inc is a specialty pharmaceutical company. The company specializes in research, development, manufacturing, and distribution of a variety of narcotic, pain-management, and addiction treatment pharmaceutical products. Aoxing holds approximately 139 drug production certificates covering narcotic pain-management, exclusive prescription medicines, OTC and API products. It derives all its revenue from the People's Republic of China.

Executives

Wilfred Chow	officer: Chief Financial Officer	30 WEST STREET, 3B, NEW YORK NY 10004
John P Oshea	director	C/O WESTMINSTER SECURITIES CORP, 100 WALL ST, 7TH FLOOR, NEW YORK NY 10005
John Leo	director, officer: Secretary	80 WALL STREET, 5TH FLOOR, NEW YORK NY 10005

Aoxing Pharmaceutical Co (Aoxing Pharmaceutical Co) Headlines

No Headlines